Treatment Options for Patients With Unresectable Colorectal Cancer With Wild-Type KRAS
- First Online:
- Cite this article as:
- Saltz, L.B. Curr Colorectal Cancer Rep (2012) 8: 170. doi:10.1007/s11888-012-0134-5
- 67 Downloads
KRAS mutation has been demonstrated to be an important marker which can be utilized to identify a subset of patients who will not benefit from, and may, in fact, be harmed by, treatment with anti- EGFR agents. The presence of an exon 2 KRAS mutation tells us not to use an anti-EGFR monoclonal antibody. A KRAS wild type result tells us that the option of using an anti-EGFR monoclonal antibody does exist, however it does not compel the use of these antibodies in first-line regimens. How and when to utilize the anti-EGFR agents in the management of patients with KRAS wild type tumors is the subject of this manuscript.